EMERALD-1: TACE plus immunotherapy meets primary endpoint in unresectable HCC Presented ByDr Riccardo Lencioni, University of Pisa, Italy TrialPhase 3, EMERALD-1 ConferenceASCO GI 2024 TypeNews article 13 February 2024 12:57